AlphaStocks
5.7
Consider Buy

BIO-TECHNE Corp (TECH)

As of Sep 20, 2026, BIO-TECHNE Corp (TECH) scores 5.7/10 on AlphaStocks' five-model composite, #70 of 168 Health Care stocks. At $72, TECH trades 109% above its model fair value of $35.

Health Care / Life Sciences Tools & Services

S&P 500

$72.40

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#70out of 168 in Health Care

Is BIO-TECHNE Corp a Good Investment in 2026?

BIO-TECHNE Corp (TECH) scores 5.7 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates BIO-TECHNE Corp as Attractive (5/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 1.8% · ROC 29%. BIO-TECHNE Corp currently trades 109% above its estimated fair value of $35. BIO-TECHNE Corp ranks #70 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E157.5ROE3.7Market Cap11B

Estimated Fair Value

$34.64109% above

Trading above estimated fair value. P/e of 158x implies high growth expectations. eps growth of -56% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield 1.8% · ROC 29%

Frequently Asked Questions

Is BIO-TECHNE Corp (TECH) a good investment?
As of Sep 20, 2026, BIO-TECHNE Corp (TECH) scores 5.7/10 on AlphaStocks' five-model composite, #70 of 168 Health Care stocks. At $72, TECH trades 109% above its model fair value of $35. That is a middle-of-the-pack score with no strong signal either way.
What is BIO-TECHNE Corp's Piotroski F-Score?
BIO-TECHNE Corp's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is TECH overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $35, TECH appears overvalued. The stock currently trades 109% above its estimated fair value. Trading above estimated fair value. P/e of 158x implies high growth expectations. eps growth of -56% may not justify the premium.
How does TECH compare to other Health Care stocks?
BIO-TECHNE Corp ranks #70 out of 168 stocks in the Health Care sector, placing it in the top 42% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about TECH?
AlphaStocks evaluates TECH using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Neutral; Lynch: Attractive; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.7/10.

Similar Stocks

BIOILMNAZTA

Compare TECH with

BIO vs TECHILMN vs TECHAZTA vs TECHPARR vs TECH

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer